NEW PATIENT APPOINTMENT PATIENT REFERRAL

Clinical Trial

Trial Protocol ID USOR 23335_R3767-ONC-22122

Trial Description

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA 

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Najeff Waseem, MD

Disease Types

Sponsor

  • Regeneron

ClinicalTrials.gov NCT ID

  • NCT06246916